/ZYME
ZYME Stock - Zymeworks Inc.
Healthcare|BiotechnologyNASDAQ
$27.23+3.14%
+$0.83 (+3.14%) • Dec 19
82
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).95
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.69
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+22.3%upside
Target: $33.30
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ZYME
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$26.96 – $27.50
TARGET (TP)$33.29
STOP LOSS$25.05
RISK/REWARD1:2.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.27
52W High$28.49
52W Low$9.03
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $76.30M | $76.01M | $412.48M | $26.68M | $38.95M |
| Gross Profit | $76.30M | $-66,977,000 | $412.48M | $26.68M | $-131,945,000 |
| Gross Margin | 100.0% | -88.1% | 100.0% | 100.0% | -338.7% |
| Operating Income | $-137,110,000 | $-138,053,000 | $130.53M | $-215,633,000 | $-187,468,000 |
| Net Income | $-122,695,000 | $-118,674,000 | $124.34M | $-211,843,000 | $-180,552,000 |
| Net Margin | -160.8% | -156.1% | 30.1% | -794.0% | -463.5% |
| EPS | $-1.62 | $-1.72 | $1.91 | $-4.06 | $-3.58 |
Company Overview
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
64%
Hold / Neutral
4
36%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
7 Bullish4 Neutral/Bearish
Price Targets
$17
Average Target
↓ 36.1% Downside
Now
$8
Low
$17
Average
$33
High
Based on 15 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 12th 2025 | Wells Fargo | Upgrade | Overweight | $33 |
| December 3rd 2025 | Citizens JMP | Initiation | Mkt Outperform | $32 |
| October 24th 2025 | Wells Fargo | Resumed | Equal Weight | $15 |
| October 14th 2025 | H.C. Wainwright | Upgrade | Buy | $26 |
| October 10th 2025 | B. Riley Securities | Initiation | Buy | $30 |
| May 20th 2025 | TD Cowen | Initiation | Buy | - |
| December 16th 2024 | JP Morgan | Upgrade | Overweight | $18 |
| November 7th 2024 | Leerink Partners | Upgrade | Outperform | $25← $10 |
| November 1st 2024 | Wells Fargo | Downgrade | Equal Weight | $12 |
| March 21st 2023 | Wells Fargo | Resumed | Overweight | $12 |
| January 4th 2023 | H.C. Wainwright | Reiterated | Neutral | $8← $10 |
| December 20th 2022 | Jefferies | Upgrade | Buy | $11← $7.7 |
| November 1st 2022 | H.C. Wainwright | Downgrade | Neutral | $8← $40 |
| October 21st 2022 | SVB Leerink | Downgrade | Market Perform | $8 |
| October 4th 2022 | Wells Fargo | Resumed | Overweight | $9← $45 |
Earnings History & Surprises
ZYMEBeat Rate
50%
Last 18 quarters
Avg Surprise
-169.8%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$-0.26
Q4 2025
EPS Surprise History
Q1 24
+48.7%
$-0.20vs$-0.39
Q2 24
-35.5%
$-0.42vs$-0.31
Q3 24
-17.4%
$-0.49vs$-0.42
Q4 24
+2.5%
$-0.39vs$-0.40
Q1 25
-3200.0%
$-0.31vs$0.01
Q2 25
+33.3%
$-0.30vs$-0.45
Q3 25
+105.8%
$0.03vs$-0.52
Q4 25
+13.3%
$-0.26vs$-0.30
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 4, 2026 | $-0.35 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.30 | $-0.26 | +13.3% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.52 | $0.03 | +105.8% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.45 | $-0.30 | +33.3% | ✓ BEAT |
Q1 2025 | Mar 5, 2025 | $0.01 | $-0.31 | -3200.0% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $-0.40 | $-0.39 | +2.5% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.42 | $-0.49 | -17.4% | ✗ MISS |
Q2 2024 | May 2, 2024 | $-0.31 | $-0.42 | -35.5% | ✗ MISS |
Q1 2024 | Mar 6, 2024 | $-0.39 | $-0.20 | +48.7% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.55 | $-0.41 | +25.5% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.51 | $-0.76 | -49.0% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-0.64 | $-0.37 | +42.2% | ✓ BEAT |
Q1 2023 | Mar 7, 2023 | $4.84 | $4.65 | -3.9% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.94 | $-0.72 | +23.4% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.93 | $-0.97 | -4.3% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.97 | $-1.19 | -22.7% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-1.06 | $-0.95 | +10.4% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-1.18 | $-1.25 | -5.9% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-1.06 | $-1.31 | -23.6% | ✗ MISS |
Latest News
Truist Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $40
📈 PositiveBenzinga•Dec 17, 2025, 12:26 PM
Wells Fargo Upgrades Zymeworks to Overweight, Raises Price Target to $33
📈 PositiveBenzinga•Dec 12, 2025, 04:29 PM
Citizens Initiates Coverage On Zymeworks with Market Outperform Rating, Announces Price Target of $32
📈 PositiveBenzinga•Dec 3, 2025, 03:58 PM
B. Riley Securities Reiterates Buy on Zymeworks, Raises Price Target to $40
📈 PositiveBenzinga•Nov 21, 2025, 04:22 PM
Wells Fargo Maintains Equal-Weight on Zymeworks, Raises Price Target to $25
➖ NeutralBenzinga•Nov 19, 2025, 02:08 PM•Also:
Stifel Maintains Buy on Zymeworks, Raises Price Target to $40
📈 PositiveBenzinga•Nov 19, 2025, 12:53 PM•Also: ,
HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $32
📈 PositiveBenzinga•Nov 18, 2025, 11:10 AM
Zymeworks Unveils Royalty Driven Strategic Initiative Following Positive Phase 3 HERIZON GEA 01 Trial Results For Ziihera In First Line GEA
📈 PositiveBenzinga•Nov 18, 2025, 06:43 AM
Market-Moving News for November 17th
➖ NeutralBenzinga•Nov 17, 2025, 12:23 PM•Also: ,
Zymeworks shares are trading higher after the company and its partners reported statistically significant and clinically meaningful improvements across PFS, OS, ORR, and DoR in the HERIZON-GEA-01 study.
📈 PositiveBenzinga•Nov 17, 2025, 12:15 PM
Jazz, Zymeworks' Ziihera trial shows significant PFS improvement, shares rally
📈 PositiveSeeking Alpha•Nov 17, 2025, 12:13 PM
Zymeworks And Partners Report Statistically Significant And Clinically Meaningful Improvements Across PFS OS ORR And DoR In HERIZON GEA 01
📈 PositiveBenzinga•Nov 17, 2025, 11:18 AM
Wells Fargo Maintains Equal-Weight on Zymeworks, Raises Price Target to $17
➖ NeutralBenzinga•Nov 7, 2025, 06:54 PM
Zymeworks Q3 EPS $(0.26) Beats $(0.35) Estimate, Sales $27.614M Miss $29.460M Estimate
➖ NeutralBenzinga•Nov 6, 2025, 09:19 PM
Zymeworks Announces Preliminary Results From Phase 1 Study Evaluating ZW191, ADC Targeting Folate Receptor-Alpha, At AACR-NCI-EORTC Conference
➖ NeutralBenzinga•Oct 23, 2025, 04:32 PM
JP Morgan Maintains Overweight on Zymeworks, Raises Price Target to $23
📈 PositiveBenzinga•Oct 16, 2025, 11:48 AM
HC Wainwright & Co. Upgrades Zymeworks to Buy, Raises Price Target to $26
📈 PositiveBenzinga•Oct 14, 2025, 11:15 AM
Zymeworks To Present Preliminary Results From Phase 1 Study Evaluating ZW191, ADC Targeting Folate Receptor-⍺, At AACR-NCI-EORTC Conference 2025.
📈 PositiveBenzinga•Oct 13, 2025, 08:02 PM
B. Riley Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $30
📈 PositiveBenzinga•Oct 10, 2025, 01:28 PM
Zymeworks shares are trading lower after the company discontinued clinical development of ZW171.
📉 NegativeBenzinga•Sep 2, 2025, 12:54 PM
Frequently Asked Questions about ZYME
What is ZYME's current stock price?
Zymeworks Inc. (ZYME) is currently trading at $27.23 per share. The stock has moved +3.14% today.
What is the analyst price target for ZYME?
The average analyst price target for ZYME is $33.29, based on 1 analyst.
What sector is Zymeworks Inc. in?
Zymeworks Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ZYME's market cap?
Zymeworks Inc. has a market capitalization of $2.05 billion, making it a mid-cap company.
Does ZYME pay dividends?
No, Zymeworks Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARDX
Ardelyx, Inc.
$5.68
Mkt Cap: $1.4B
BCRX
BioCryst Pharmaceuticals, Inc.
$7.41
Mkt Cap: $1.6B
IMNM
Immunome, Inc.
$21.44
Mkt Cap: $2.0B
MAZE
Maze Therapeutics, Inc.
$41.71
Mkt Cap: $2.0B
NTLA
Intellia Therapeutics, Inc.
$9.23
Mkt Cap: $1.0B
PHVS
Pharvaris N.V.
$25.59
Mkt Cap: $1.7B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
TRVI
Trevi Therapeutics, Inc.
$13.01
Mkt Cap: $1.7B
UPB
Upstream Bio, Inc.
$29.35
Mkt Cap: $1.6B
WVE
Wave Life Sciences Ltd.
$15.98
Mkt Cap: $2.6B
Explore stocks similar to ZYME for comparison